https://scholars.lib.ntu.edu.tw/handle/123456789/565742
標題: | Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease | 作者: | Wong J.-M. SHU-CHEN WEI |
關鍵字: | Aminosalicyclic acids; Comparative study; Delayed-action preparations; Inflammatory bowel diseases; Mesalamine | 公開日期: | 2003 | 卷: | 102 | 期: | 9 | 起(迄)頁: | 613-619 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background and Purpose: The Eudgragit S formulation of delayed-release 5-aminosalicylic acid (5-ASA), Asacol? tablets (AT), has limited efficacy in maintaining remission in patients with inflammatory bowel disease (IBD). This study evaluated the effect of switching patients with unsatisfactory results under treatment with AT to a microgranule delayed-release formulation of 5-ASA, Pentasa? tablets (PT). Methods: A 12-week, open drug-switching study was conducted in 15 IBD patients, including 9 with ulcerative colitis (UC) and 6 with Crohn's disease (CD) who were evaluated at the time of switching from routine AT (2.4 g/day) treatment (for more than 3 months)to PT (4 g/day). UC patients were those under AT remission maintenance and they were defined as prone-to-relapse because of endoscopy scores ? 2. CD patients were those under acute treatment with AT who had not attained a complete remission. The primary endpoint was the change in UC Disease Activity Index (UC-DAI) or the CD Activity Index scores after switching to PT therapy. Drug safety profile and patient acceptability were secondary endpoints. Results: Twelve weeks after switching to PT treatment, the mean (± SEM) UC-DAI score was reduced significantly, from 8.18 ± 0.58 to 6.81 ± 0.72 (p = 0.013) in UC patients. Subcategory scores indicated improvements in endoscopy scores and in physician global assessment. Though the change in clinical outcomes did not reach significance for CD patients, a trend towards a therapeutic benefit was observed. No adverse event was observed during the 12-week clinical trial. Conclusion: PT may provide a better alternative for IBD patients with unsatisfactory response to AT therapy. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0346496079&partnerID=40&md5=97a184fbfa658629e01090a334363f7a https://scholars.lib.ntu.edu.tw/handle/123456789/565742 |
ISSN: | 0929-6646 | SDG/關鍵字: | mesalazine; adult; article; clinical article; clinical trial; controlled clinical trial; controlled study; Crohn disease; delayed release formulation; disease activity; drug efficacy; drug safety; endoscopy; enteritis; female; hematologic disease; human; kidney dysfunction; liver dysfunction; maintenance therapy; male; open study; patient compliance; relapse; remission; scoring system; statistical significance; treatment outcome; ulcerative colitis; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Middle Aged; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。